Your browser is no longer supported. Please, upgrade your browser.
Settings
OMER Omeros Corporation daily Stock Chart
OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-1.47 Insider Own0.50% Shs Outstand46.80M Perf Week3.19%
Market Cap968.29M Forward P/E- EPS next Y-0.70 Insider Trans-14.29% Shs Float44.71M Perf Month-6.08%
Income-63.00M PEG- EPS next Q-0.33 Inst Own46.90% Short Float19.27% Perf Quarter-16.87%
Sales53.60M P/S18.07 EPS this Y17.50% Inst Trans8.38% Short Ratio8.82 Perf Half Y86.06%
Book/sh-1.25 P/B- EPS next Y46.20% ROA-97.40% Target Price38.60 Perf Year82.45%
Cash/sh0.63 P/C32.60 EPS next 5Y- ROE154.50% 52W Range7.20 - 27.09 Perf YTD108.57%
Dividend- P/FCF- EPS past 5Y-5.10% ROI-141.50% 52W High-23.62% Beta3.57
Dividend %- Quick Ratio2.10 Sales past 5Y55.90% Gross Margin97.80% 52W Low187.36% ATR1.01
Employees154 Current Ratio2.10 Sales Q/Q72.00% Oper. Margin- RSI (14)47.39 Volatility3.96% 4.76%
OptionableYes Debt/Eq- EPS Q/Q-1.30% Profit Margin- Rel Volume0.40 Prev Close20.96
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume976.55K Price20.69
Recom1.80 SMA200.42% SMA50-2.97% SMA20031.69% Volume395,234 Change-1.29%
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Mar-18-15Reiterated Needham Buy $22 → $32
Feb-20-15Reiterated Maxim Group Buy $28 → $30
Feb-18-15Reiterated MLV & Co Buy $19 → $38
Nov-13-14Reiterated Maxim Group Buy $20 → $28
Mar-25-14Reiterated Needham Buy $15 → $17
Apr-15-13Initiated MLV & Co Buy $14
Mar-19-13Resumed Needham Buy $12
Dec-28-12Reiterated Burrill Institutional Research Mkt Outperform $19 → $16
Sep-12-17 12:19AM  ETFs with exposure to Omeros Corp. : September 12, 2017 Capital Cube
Aug-31-17 07:54PM  ETFs with exposure to Omeros Corp. : August 31, 2017 Capital Cube
Aug-25-17 11:04AM  Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-23-17 11:00AM  Omeros Responds to Statnews.com Story Business Wire
Aug-22-17 09:46AM  Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers TheStreet.com
09:02AM  Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017 Capital Cube
Aug-21-17 03:25PM  Omeros Closes $68.3 Million Public Offering of Common Stock Business Wire -5.58%
Aug-15-17 09:34AM  Omeros's stock sinks after share offering prices at a discount MarketWatch -8.49%
09:17AM  Omeros Announces Pricing of Public Offering of Common Stock Business Wire
Aug-14-17 04:05PM  Omeros Announces Public Offering of Common Stock Business Wire
12:55PM  Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721 Business Wire
Aug-13-17 11:25AM  Edited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:00AM  Today's Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals ACCESSWIRE -5.38%
07:00AM  Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire
Aug-08-17 05:49PM  Omeros reports 2Q loss Associated Press
04:02PM  Omeros Corporation Reports Second Quarter 2017 Financial Results Business Wire
11:00AM  Investor Network: Omeros Corporation to Host Earnings Call ACCESSWIRE
07:10AM  Corporate News Blog - FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of IgA Nephropathy ACCESSWIRE
Aug-04-17 11:10AM  FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of IgA Nephropathy Business Wire +6.93%
Aug-02-17 07:00AM  Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017 Business Wire
Jul-25-17 06:30AM  3 Stocks That Could Put Nvidia's Returns to Shame Motley Fool
Jul-17-17 08:50AM  Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation Accesswire
Jul-12-17 11:01AM  Technical trading: These four stocks are breaking out of their pattern MarketWatch
Jul-06-17 05:45PM  Omeros threatens to sue anonymous detractor American City Business Journals
Jul-03-17 09:24AM  Biotech Movers: BioCryst, Omeros, Radius Health TheStreet.com
Jun-29-17 08:41AM  Omeros to pursue legal action against short seller for report that shaved 21% off stock this week MarketWatch
08:39AM  Omeros Corporation (OMER) Accuses Short Seller of Manipulation SmarterAnalyst
07:00AM  Omeros Releases Statement in Response to Recent False Report Business Wire
Jun-28-17 04:02PM  Here's Why Omeros Corporation Fell as Much as 14.8% Today Motley Fool -9.48%
Jun-27-17 04:27PM  These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing? Motley Fool -9.36%
Jun-19-17 08:00AM  Today's Research Reports on Stocks to Watch: ReWalk Robotics and Omeros Corporation Accesswire
Jun-17-17 07:32AM  3 Stocks Wall Street Hasn't Noticed Motley Fool
Jun-16-17 10:53AM  Omeros (OMER) Hits New 52-Week High on Positive FDA Decision Zacks +7.22%
Jun-15-17 04:05PM  These 3 Stocks Could Have Doubled Your Money This Year Motley Fool
08:48AM  Harry Boxer: 4 stocks with strong technical momentum MarketWatch
Jun-14-17 02:09PM  2 Longs And 2 Shorts To Watch Benzinga +12.21%
10:27AM  Omeros (OMER) Lead Candidate Gets Breakthrough Designation Zacks
Jun-13-17 04:29PM  Why Tesla, Omeros, and Hertz Global Holdings Jumped Today Motley Fool +14.50%
04:06PM  Omeros Corporations Breakthrough Becomes a Clear Danger to Alexion: WBB SmarterAnalyst
04:05PM  Here's Why Omeros Corporation Stock Rose as Much as 16.7% Today Motley Fool
12:48PM  ETFs with exposure to Omeros Corp. : June 13, 2017 Capital Cube
11:30AM  FDA Grants Breakthrough Therapy Designation to Omeros MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy Business Wire
08:30AM  Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session Zacks
08:26AM  Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : June 13, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Coherus Biosciences and Omeros Corporation Accesswire
Jun-07-17 09:42AM  Omeros: Can the Growth Story Continue? Motley Fool
08:45AM  5 Top Stocks for June Motley Fool
Jun-05-17 04:29PM  3 Stocks With Exelixis-Like Return Potential Motley Fool
Jun-01-17 02:01PM  ETFs with exposure to Omeros Corp. : June 1, 2017 Capital Cube
07:00AM  Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress Business Wire
May-22-17 01:58PM  ETFs with exposure to Omeros Corp. : May 22, 2017 Capital Cube
May-19-17 10:23AM  Omeros Corp. :OMER-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-18-17 08:15AM  Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results Accesswire
May-17-17 12:03PM  Here's Why Omeros Corporation Is Surging Again Today Motley Fool +8.70%
07:00AM  Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial Business Wire
May-16-17 07:16PM  Edited Transcript of OMER earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-15-17 04:31PM  3 Biotech Stocks I'd Buy Right Now Motley Fool
May-11-17 12:28PM  Here's Why Omeros Corporation Stock Is Falling Today Motley Fool -8.30%
May-10-17 04:36PM  Omeros reports 1Q loss Associated Press
04:02PM  Omeros Corporation Reports First Quarter 2017 Financial Results Business Wire
10:15AM  Investor Network: Omeros Corporation to Host Earnings Call Accesswire
May-03-17 04:02PM  Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017 Business Wire
Apr-17-17 09:28AM  Biotech Movers: OncoMed, Incyte, Omeros TheStreet.com
Apr-15-17 12:02PM  3 Biotech Stocks to Buy on Sale Motley Fool
Apr-03-17 07:00AM  Omeros to Present at the Needham Healthcare Conference Business Wire
Mar-30-17 09:54AM  Biotech Premarket Movers: Halozyme, Omeros, Aralez TheStreet.com +7.50%
09:54AM  Biotech Premarket Movers: Halozyme, Omeros, Aralez
07:00AM  Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases Business Wire
Mar-29-17 08:34PM  ETFs with exposure to Omeros Corp. : March 30, 2017 Capital Cube
08:34PM  ETFs with exposure to Omeros Corp. : March 30, 2017
04:21PM  Top Biotech Stocks for Growth Investors Motley Fool
04:21PM  Top Biotech Stocks for Growth Investors at Motley Fool
09:30AM  Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug Accesswire
Mar-28-17 05:03PM  Here's Why Omeros Corporation Stock Climbed Higher Today Motley Fool +11.29%
05:03PM  Here's Why Omeros Corporation Stock Climbed Higher Today at Motley Fool
12:24PM  3 Stocks That Could Make You Rich Motley Fool
12:24PM  3 Stocks That Could Make You Rich at Motley Fool
07:00AM  Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation Business Wire
Mar-27-17 07:00AM  Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology Business Wire +9.60%
Mar-24-17 09:02AM  Omeros: Power in the Pipeline at Motley Fool
Mar-23-17 01:04PM  OMEROS CORP Financials
Mar-21-17 09:30AM  Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Accesswire -5.36%
09:29AM  Omeros Corp. :OMER-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
08:22AM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
Mar-20-17 08:19AM  Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : March 20, 2017 +11.48%
Mar-17-17 04:11PM  Edited Transcript of OMER earnings conference call or presentation 16-Mar-17 8:30pm GMT -9.14%
Mar-16-17 04:34PM  Omeros reports 4Q loss
04:30PM  Omeros Corp Earnings Call scheduled for 4:30 pm ET today
04:07PM  OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results Business Wire
07:07AM  Q4 2016 Omeros Corp Earnings Release - After Market Close
Mar-14-17 02:05PM  5 Earnings Short-Squeeze Plays: Tiffany, Athene and More
Mar-10-17 07:00AM  Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017 Business Wire
Mar-02-17 07:00AM  Omeros to Present at the Cowen and Company Annual Health Care Conference Business Wire
Mar-01-17 07:00AM  Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire
Feb-26-17 03:09PM  3 Stocks That Could Make You Rich at Motley Fool
Feb-08-17 07:25AM  Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : February 8, 2017
Jan-19-17 01:40PM  ETFs with exposure to Omeros Corp. : January 19, 2017
Jan-03-17 02:37PM  ETFs with exposure to Omeros Corp. : January 3, 2017
Dec-23-16 09:35AM  Omeros Corp. Value Analysis (NASDAQ:OMER) : December 23, 2016 +7.22%
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The company's preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelbon Marcia S.VP Patent and General CounselAug 21Option Exercise6.058,00048,400176,641Aug 21 03:21 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 16Option Exercise9.3714,000131,18019,500Jun 16 08:01 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 16Sale24.9512,000299,4007,500Jun 16 08:01 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 15Option Exercise9.3714,000131,18017,500Jun 15 07:02 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 15Sale22.4512,000269,4005,500Jun 15 07:02 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 14Option Exercise9.3712,850120,40512,850Jun 15 07:02 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 14Sale19.959,350186,5333,500Jun 15 07:02 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 13Option Exercise9.372,65024,8312,650Jun 15 07:02 PM
JACOBSEN MICHAEL AVP Finance and CAOJun 13Sale19.952,65052,8680Jun 15 07:02 PM
Cable Thomas J.DirectorApr 12Sale16.493,00049,47440,067Apr 14 02:04 PM
Kelbon Marcia S.VP Patent and General CounselMar 20Option Exercise6.052,04012,342168,641Mar 22 04:06 PM
Cable Thomas J.DirectorDec 14Sale10.213,00030,64243,067Dec 16 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 07Option Exercise0.98102,044100,0031,987,029Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 07Sale10.48102,0441,069,0331,884,985Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 06Option Exercise0.98102,04099,9991,987,025Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 06Sale10.80102,0401,101,8081,884,985Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 05Option Exercise0.98102,04099,9991,987,025Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 05Sale10.71102,0401,092,6441,884,985Dec 07 09:00 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 02Option Exercise0.98283,203277,5391,884,985Dec 02 09:40 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 02Sale11.00102,0401,122,5931,703,822Dec 02 09:40 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 01Option Exercise0.98106,521104,3911,810,343Dec 02 09:40 PM
Demopulos Gregory A MDChairman, CEO & PresidentDec 01Sale11.57106,5211,232,0631,703,822Dec 02 09:40 PM
Demopulos Gregory A MDChairman, CEO & PresidentNov 30Option Exercise0.9897,55995,6081,801,381Dec 02 09:40 PM
Demopulos Gregory A MDChairman, CEO & PresidentNov 30Sale12.2197,5591,191,4781,703,822Dec 02 09:40 PM
Kelbon Marcia S.VP Patent and General CounselOct 12Option Exercise6.053,00418,174166,601Oct 12 09:00 PM